±³½Ç¼Ò°³

    • home
    • ±³½Ç¼Ò°³
    • ±âÃÊÀÇÇÐ

±âÃÊÀÇÇÐ

  • ÀüÀÓ±³¼ö(ÀÇ°ú´ëÇÐ)
  • ÀÌÀ±¼Û
  • ȨÆäÀÌÁö ¹Ù·Î°¡±â http://biomed.skku.edu/yslee
  • Àü°øºÐ¾ß £ü µ¶¼º¾à¸®ÇÐ, ºÐÀھฮÇÐ, ½Å°æ¾à¸®ÇÐ
  • ¿¬¶ôó     £ü (ÀüÈ­) 031-299-6190 / (fax) 031-299-6209
  • À̸ÞÀÏ     £ü yslee@skku.edu

ÁÖ¿ä°æ·Â

  • 1988 ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐÀÇÇлç
    1993 ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐÀÇÇйڻç(¾à¸®ÇÐ)
    1997 – 1998 ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ÀüÀÓ°­»ç
    1998 – 2001 ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ Á¶±³¼ö
    2001 – 2002 ¹Ì±¹Univ. California, San Diego, Visiting scientist (±¹Á¦¾ÏÇÐȸ fellowship)
    2003 – 2009 ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ±³¼ö
    2009 - ÇöÀç ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ±³¼ö

ÁÖ¿ä°ü½É¿¬±¸

  • ¸¸¼ºÆó¼â¼ºÆóÁúȯ(chronic obstructive pulmonary disease, COPD)

    Èí¿¬¿¡ ÀÇÇÑ ÆóÀÇ ¸¸¼º¿°Áõ¼ºÁúȯÀÎ COPD´Â ÇöÀç ±¹³» 10´ë »ç¸Á¿äÀÎÀ̸ç, 2010³â¿¡´Â ¼¼°èÀûÀ¸·Î »ç¸Á ¹× ºÒ±¸¸¦ À¯¹ßÇÏ´Â 4À§ÀÇ ÁúȯÀÌ µÉ °ÍÀ¸·Î Àü¸ÁÇÏ°í ÀÖ´Ù. Àû±ØÀûÀÎ ±Ý¿¬ ¿îµ¿¿¡µµ ºÒ±¸ÇÏ°í ÇöÀç±îÁöµµ COPDÀÇ À¯º´·ü ¹× »ç¸Á·üÀº Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÏ´Â Ãß¼¼ÀÌ´Ù. ±× ÀÌÀ¯ Áß Çϳª´Â, COPD ºÐ¾ß¿¡¼­ Áö¼ÓÀûÀÎ ¿¬±¸¿¡µµ ºÒ±¸ÇÏ°í ¾ÆÁ÷±îÁöµµ COPDÀÇ º´ÀÎ ±âÀüÀ» Àß ÀÌÇØÇÏÁö ¸øÇÏ°í ÀÖÀ¸¸ç, µû¶ó¼­, Á¶±â Áø´Ü(early diagnosis) ¹× ±ÙÄ¡ÀûÀÎ Ä¡·á(curative therapy)°¡ Àü¹«ÇÏ´Ù´Â °ÍÀÌ´Ù. µû¶ó¼­, º» ¿¬±¸ÁøÀº COPDÀÇ ¹ßº´±âÀüÀ» ¿¬±¸ÇÏ¿©, Á¶±â Áø´Ü ¹× ±ÙÄ¡Àû Ä¡·á¸¦ À§ÇÑ Áø´Ü/Ä¡·á Ç¥ÀûÀ» Ž»öÇÏ°í, À̸¦ ÀÌ¿ëÇÏ¿© »õ·Î¿î Áø´Ü/Ä¡·á¹ýÀ» °³¹ßÇÏ°íÀÚ ³ë·ÂÇÏ°í ÀÖ´Ù. ÃÖ±Ù º» ¿¬±¸ÁøÀº, Ç×ÄÝ·¹½ºÅ×·Ñ Á¦Á¦ÀÎ simvastatin(HMG-CoA reductase inhibitor)°ú ´ç´¢º´ Ä¡·áÁ¦ÀÎ rosiglitazone(PPAR-g ligand)ÀÌ Èí¿¬¿¡ ÀÇÇÑ COPDÀÇ ¹ßº´À» È¿°úÀûÀ¸·Î ¾ïÁ¦ÇÏ´Â °ÍÀ» ¾Ë¾Æ³»¾ú´Ù. ¶ÇÇÑ, ±ÙÄ¡ÀûÀÎ Ä¡·á·Î¼­ °ñ¼öÀ̽Ŀ¡ ÀÇÇÑ ÆóÁ¶Á÷ Àç»ýµµ È¿°úÀûÀÎ °ÍÀ» °üÂûÇÏ¿´´Ù. ÇöÀç º» ¿¬±¸ÁøÀº ÀÌµé °¡´É¼º ÀÖ´Â Ä¡·á¹ý(potentially therapeutic regimens)ÀÇ ¼¼Æ÷³»,¿Ü ±âÀü(½ÅÈ£Àü´Þ°è, ƯÁ¤ À¯ÀüÀÚÀÇ Á¶Àý ±âÀü µî)À» ¿¬±¸ÇÔÀ¸·Î½á Á¤È®ÇÑ Ä¡·á ±âÀü/Ç¥ÀûÀ» ¹àÈ÷°í À̸¦ ÅëÇØ ÀÌ»óÀûÀÎ COPD Ä¡·á¹ýÀ» µµÃâÇÏ°íÀÚ ¼¼ºÎ ¿¬±¸¸¦ Áö¼ÓÇÏ°í ÀÖ´Ù. ÇöÀç ¿¬±¸ ¹æÇâÀº, Ç׿°Áõ, Á¶Á÷ Àç»ý, ¼¼Æ÷°í»ç/¼¼Æ÷Áõ½Ä, stem cell, ´Ü¹éºÐÇØ ¹× ¼¼Æ÷¿Ü ±âÁú Çü¼º, °ü·Ã ½ÅÈ£Àü´Þ°è, ¹ßº´ ¹× ¹ßº´ ¾ïÁ¦ À¯ÀüÀÚ ½ºÅ©¸®´×, °ü·Ã À¯ÀüÀÚ ¹ßÇö°ú Á¶Àý µîÀÇ ±âÀü ¿¬±¸°¡ Áß½ÉÀÌ´Ù.

´ëÇ¥¿¬±¸¾÷Àû

  • 1. Huh JW, Kim SY, Lee JH, Lee JS, Van Ta Q, Kim M, Oh YM, Lee YS, Lee SD. Bone marrow cells repair cigarette smoke-induced emphysema in rats. Am J Physiol Lung Cell Mol Physiol. 2011 Sep301(3):L255-66. doi: 10.1152/ajplung.00253.2010. Epub 2011 May 27.

    2. Kim SY, Kim HJ, Park MK, Huh JW, Park HY, Ha SY, Shin JH, Lee YS. Mitochondrial E3 Ubiquitin Protein Ligase 1 Mediates Cigarette Smoke-Induced Endothelial Cell Death and Dysfunction. Am J Respir Cell Mol Biol. 2016 Feb54(2):284-96. doi: 10.1165/rcmb.2014-0377OC.

    3. Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, Oh YM, Lee SD, Lee YS. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2012 Nov47(5):698-708. doi: 10.1165/rcmb.2011-0331OC. Epub 2012 Jul 27.

    4. Kim SY, Lee JH, Huh JW, Ro JY, Oh YM, Lee SD, An S, Lee YS. Cigarette smoke induces Akt protein degradation by the ubiquitin-proteasome system. J Biol Chem. 2011 Sep 16286(37):31932-43. doi: 10.1074/jbc.M111.267633. Epub 2011 Jul 21.

    5. Kim SY, Lee JH, Kim HJ, Park MK, Huh JW, Ro JY, Oh YM, Lee SD, Lee YS. Mesenchymal stem cell-conditioned media recovers lung fibroblasts from cigarette smoke-induced damage. Am J Physiol Lung Cell Mol Physiol. 2012 May 1302(9):L891-908. doi: 10.1152/ajplung.00288.2011. Epub 2012 Feb 3.

    6. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 Oct 15172(8):987-93. Epub 2005 Jul 7.